Skip to content


LIDDS was founded based on an invention that enables a controlled and sustained local release of drugs, later called the NanoZolid technology. The first patent application covering this invention was filed in 2003. The primary focus of the company for the first 15 years was the development of Liproca Depot for the treatment of prostate cancer patients.


LIDDS enters into an R&D agreement with Johnson & Johnson Enterprise Innovation Inc. Extensive management changes and a strategic review are conducted within LIDDS. The phase I clinical study investigating nanodotax in different solid tumors is closed.


The first patient is treated in the clinical phase I study with nanodotax. Positive preclinical results regarding tumor control and survival are reported with a NanoZolid-formulated TLR9 agonist in the nanoimod project.


Results from the phase llb study with Liproca Depot show clinical efficacy in prostate cancer patients.


LIDDS signs a license agreement with Puheng Pharma for prostate cancer drug Liproca Depot and the Chinese market.


The phase IIb study with Liproca Depot is initiated in Canada and Finland.


A preclinical study is concluded on local treatment with NanoZolid-formulated docetaxel. The study shows a clear treatment effect without the negative side effects that systemic administration generates. Based on the positive results, LIDDS chose to further develop the project and today the project is called nanodotax.


LIDDS receives patent approvals for NanoZolid on all major markets. LIDDS enters into a collaboration with Recipharm on the manufacturing of Liproca Depot.


The company’s shares are listed on the Nasdaq First North Growth Market.


The Liproca Depot clinical phase IIa trial initiated in 2012 is concluded and shows a clear decrease in the tumor marker Prostate-Specific Antigen (PSA) and a decrease in prostate volume.


A supplementary clinical phase IIa study on Liproca Depot is initiated in clinical sites in Sweden and Finland.


The clinical phase IIa trial initiated in 2009 is completed and the results presented at the annual congress of the European Associations of Urology.


Important patents based on the printing process are approved in Europe.


LIDDS initiates a clinical phase IIa study investigating Liproca Depot in patients with prostate cancer.


Liproca Depot is evaluated in preclinical models.


The first clinical study investigating an early drug product and its effect in patients with prostate cancer is initiated.


The development of a user-friendly injection applicator is initiated.


LIDDS succeeds in producing 2-hydroxyflutamide (2-HOF) with a quality that meets the industry standard Good Manufacturing Practice (GMP).


A clinical development strategy is developed for Liproca Depot.


LIDDS begins developing a drug that is more effective and leads to less and milder side effects for the treatment of prostate cancer patients.